89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors
June 04 2020 - 8:00AM
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases, today announced the appointment of Lota
S. Zoth, CPA to its Board of Directors and as Chair of the Audit
Committee. A veteran of the biopharmaceutical industry, Ms. Zoth
brings more than 35 years of financial and strategic experience to
her role.
“We are very pleased to have someone of Lota’s
caliber join 89bio’s Board of Directors,” said Rohan Palekar, CEO
of 89bio. “Lota brings decades of financial, operational and board
experience to 89bio, which we expect will prove valuable as we
advance the clinical development of BIO89-100 and execute against
our goals as a public company.”
Ms. Zoth currently serves as the chair of the
board of directors and the audit committee of Zymeworks, Inc. and
as chair of the audit committees of Inovio Pharmaceuticals, Inc.
and Lumos Pharma, Inc. She previously served on the board of
directors of other biopharmaceutical companies including Spark
Therapeutics, Inc., Hyperion Therapeutics, Inc. Orexigen
Therapeutics, Inc., Aeras, Ikaria, Inc. and Circassia
Pharmaceuticals, plc. Ms. Zoth served as chief financial officer of
MedImmune, Inc. until her retirement in July 2007. Prior to
MedImmune, she held senior financial positions at a number of
publicly traded companies, including Sodexho Marriott Services,
Inc., PSINet, Inc., Marriott International, Inc. and PepsiCo, Inc.
Ms. Zoth is a certified public accountant and began her career as
an auditor at Ernst & Young, LLP. She received a BBA in
accounting, summa cum laude, from Texas Tech University.
"I'm excited to join 89bio’s Board of Directors
during this pivotal period of growth and scientific advancement,”
said Ms. Zoth. “I look forward to collaborating with other members
of the Board of Directors and company management to successfully
execute on our vision of delivering differentiated medicines to
patients with liver and cardio-metabolic diseases.”
About 89bio89bio is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of innovative therapies for the treatment of
liver and cardio-metabolic diseases. The company’s lead product
candidate, BIO89-100, is being developed for the treatment of NASH.
The company also intends to develop BIO89-100 for the treatment of
SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog
of FGF21 that is currently in a proof of concept Phase 1b/2a
clinical trial in patients with NASH or NAFLD and a high risk of
NASH. 89bio is headquartered in San Francisco with operations in
Herzliya, Israel. Visit 89bio.com for more information.
Investor Contact: Ryan Martins Chief Financial Officer
investors@89bio.com
Media Contact: Lori Rosen LDR Communications 917-553-6808
lori@ldrcommunications.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2023 to Apr 2024